Antithrombotic treatment: Thrombosis risk and bleeding risk assessment

2018-11-23
Mark Crowther

How to correctly assess the risk for thrombosis and risk for bleeding when starting or continuing antithrombotic treatment?

Mark Crowther, MD: Most of the time when antithrombotic therapy is being initiated, it is being initiated because of the presence of a life-threatening condition: atrial fibrillation with a risk of stroke or systemic embolization, acute deep vein thrombosis, or pulmonary embolism. What treating clinicians know pretty intuitively, I think, is that particularly acute deep vein thrombosis or pulmonary embolism are potentially fatal conditions. And so when you are starting a person on anticoagulants, it is very rare that you think that the risk of bleeding or other complications of the antithrombotic therapy exceeds the benefit.

Very rarely a patient might have a specific reason like active bleeding or an allergy like heparin-induced thrombocytopenia, which would affect your choice of anticoagulants, but for the vast majority of patients it is the thrombosis, not the acute bleeding, that is the decision-maker for initial therapy.

For most patients with acute deep vein thrombosis, you treat them the same way with low-molecular-weight heparin transition to warfarin or one of the newer agents.

For atrial fibrillation, again, either with warfarin or one of the other vitamin K antagonists or one of the newer agents there is relatively little risk modification or dose modification based on the patient’s initial presentation.

We would love to hear from you

Comments, mistakes, suggestions?

Partner

Industry Partners

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.